AURAAura BiosciencesRunning, no new patients
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Choroidal Melanoma · Indeterminate Lesions · Uveal Melanoma · Ocular Melanoma
6Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +5.5
Announced layoffs or restructuring
Since Aug 11, 2026 · was worth 15, fading over time
Worry score6
Score over time
- Stage
- Phase 3
- Patients
- 108 (final count)
- Started
- Dec 6, 2023
- Main results expected
- Nov 15, 2027
- Fully finished
- Aug 15, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Time to reach tumor progression
Measured over: 65 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- layoffs: base 15, now 5.5, since 2026-08-11, fades (half-life) · source filing
Raw record changes
- none yet
Trial ID NCT06007690 · record last updated 2026-10-13 · checked 2026-11-09 15:47 UTC